Journal of Urology publishes outperformance of Cxbladder

Company Announcement
18 August 2021


THE JOURNAL OF UROLOGY PUBLISHES OUTPERFORMANCE OF CXBLADDER IN USA
COVID19 SETTING

The American Urological Association’s (AUA) Journal of Urology has published the real world lookback highlighting
the clinical utility of Cxbladder being used in the Covid setting for managing patients outside the clinic. The lookback
study concluded that the use by physicians of Cxbladder Monitor and Pacific Edge’s Patient-In-Home Sampling
System reduced the number of cystoscopies required and was feasible and safe for patients being monitored for
urothelial cancer during the Covid-19 pandemic. In addition, the study concluded that Cxbladder could be used to
further stratify low risk patients for decreased surveillance during the pandemic and beyond.

The evaluation and lookback was performed by the University of California San Francisco (UCSF) on a cohort of 52
patients who were being monitored for urothelial cancer as part of their standard of care. Cxbladder Monitor
correctly identified those at high risk who immediately underwent cystoscopy. Those patients with low Cxbladder
Monitor scores were deemed to be low risk and their cystoscopies were deferred to their next scheduled
surveillance visit. The follow-up surveillance cystoscopy for these patients, showed no suspicious tumors and no
positive cytology was detected. Cxbladder Monitor missed no tumors and among those detected, a number were
high impact tumors.

CEO of Pacific Edge, David Darling, said: “This latest published evidence provides a real-world insight into the
effectiveness of Cxbladder in helping manage patients who can’t come in to the clinic. It is great to see our Patient
In-Home Sampling System (PIHSS) being used with such great effect and such compelling results.

“The COVID-19 pandemic has brought unprecedented changes to the provision of urologic care in order to minimise
risks of transmission. Advances in telemedicine look to be providing a new paradigm for healthcare and Cxbladder
and our patient in home sample system are well positioned to continue as an integral part in the detection and
management of patients with urothelial cancer.”

The clinical paper was authored by Carrisa Chu, Kevin Li, Maxwell Meng and Sima Porten and published in the
September 2021 issue of the Journal of Urology:
PD63-12:USE OF CXBLADDER MONITOR DURING THE COVID-19 PANDEMIC TO REDUCE THE FREQUENCY OF
SURVEILLANCE CYSTOSCOPY

ENDS

For more information contact: David Darling, Chief Executive Officer, Pacific Edge Ltd, P: +64 (3) 479 5800

For media assistance, please contact: Jackie Ellis, P: +64 27 246 2505 E: jackie@ellisandco.co.nz


OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of
non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of
urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through

Company Announcement
18 August 2021
its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in
international multi-centre clinical studies.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients
with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low
probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a
patients’ urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the
cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a
recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior
history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial
carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients
for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder
Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage,
Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late
stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for
further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.